Panbela Therapeutics (PBLA) Stock Price, News & Analysis

Company Overview

Panbela Therapeutics, Inc. (OTCMKTS: PBLA) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. Its research has centered on treatments that target cellular polyamine metabolism, a process involved in tumor growth and progression.

The company’s lead investigational product, SBP-101, is a polyamine metabolic inhibitor that has been studied in patients with metastatic pancreatic ductal adenocarcinoma and other advanced cancers. Panbela has also pursued therapies for familial adenomatous polyposis, an inherited condition that can cause numerous precancerous growths in the colon and rectum.

Panbela’s development activities have primarily involved clinical research and collaborations in the United States. The company’s programs have remained investigational and subject to clinical and regulatory review; its products are not established as broadly approved treatments based solely on the company’s development work.

Key Stats

• Today's Range: $0.0010 to $0.0010
• 50-Day Range: $0.0001 to $0.0111
• 52-Week Range: $0.00 to $0.10
• Volume: 30,035 shs
• Average Volume: 1,998 shs
• Market Capitalization: $4.86 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Panbela Therapeutics Stock Analysis - MarketRank™

Panbela Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Panbela Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Panbela Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Panbela Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Panbela Therapeutics does not currently pay a dividend.

Dividend Growth

Panbela Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Panbela Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Panbela Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.01% of the stock of Panbela Therapeutics is held by insiders.

Percentage Held by Institutions

4.37% of the stock of Panbela Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/10/2023
• Today: 10/16/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:PBLA
• CIK: 1029125
• Web: www.panbela.com
• Phone: (952) 479-1196
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,855,000
• Free Float: 4,855,000
• Market Cap: $4.86 thousand
• Optionable: Not Optionable
• Beta: 29.41